Cargando…
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255948/ https://www.ncbi.nlm.nih.gov/pubmed/35803289 http://dx.doi.org/10.1016/S1473-3099(22)00311-5 |
_version_ | 1784741016745541632 |
---|---|
author | Focosi, Daniele McConnell, Scott Casadevall, Arturo Cappello, Emiliano Valdiserra, Giulia Tuccori, Marco |
author_facet | Focosi, Daniele McConnell, Scott Casadevall, Arturo Cappello, Emiliano Valdiserra, Giulia Tuccori, Marco |
author_sort | Focosi, Daniele |
collection | PubMed |
description | Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents. |
format | Online Article Text |
id | pubmed-9255948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92559482022-07-06 Monoclonal antibody therapies against SARS-CoV-2 Focosi, Daniele McConnell, Scott Casadevall, Arturo Cappello, Emiliano Valdiserra, Giulia Tuccori, Marco Lancet Infect Dis Review Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents. Elsevier Ltd. 2022-11 2022-07-05 /pmc/articles/PMC9255948/ /pubmed/35803289 http://dx.doi.org/10.1016/S1473-3099(22)00311-5 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Focosi, Daniele McConnell, Scott Casadevall, Arturo Cappello, Emiliano Valdiserra, Giulia Tuccori, Marco Monoclonal antibody therapies against SARS-CoV-2 |
title | Monoclonal antibody therapies against SARS-CoV-2 |
title_full | Monoclonal antibody therapies against SARS-CoV-2 |
title_fullStr | Monoclonal antibody therapies against SARS-CoV-2 |
title_full_unstemmed | Monoclonal antibody therapies against SARS-CoV-2 |
title_short | Monoclonal antibody therapies against SARS-CoV-2 |
title_sort | monoclonal antibody therapies against sars-cov-2 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255948/ https://www.ncbi.nlm.nih.gov/pubmed/35803289 http://dx.doi.org/10.1016/S1473-3099(22)00311-5 |
work_keys_str_mv | AT focosidaniele monoclonalantibodytherapiesagainstsarscov2 AT mcconnellscott monoclonalantibodytherapiesagainstsarscov2 AT casadevallarturo monoclonalantibodytherapiesagainstsarscov2 AT cappelloemiliano monoclonalantibodytherapiesagainstsarscov2 AT valdiserragiulia monoclonalantibodytherapiesagainstsarscov2 AT tuccorimarco monoclonalantibodytherapiesagainstsarscov2 |